CORUS Clinical Nutrition

For cliniciansProduct overview
Prelaunch materials · November 2026

← Back to the CORUS site

Product overview for care teams

The first CORUS product is an unflavored powder in development as a medical food.

Download the overview as a PDF2 pages, 45 KB, US Letter

What it is

An unflavored powder made with whey protein, HMB and vitamin D, packed in individual sachets. It is designed to be added to food the person already eats. It is not intended as a meal replacement or a sole source of nutrition.

Proposed intended use

The dietary management of sarcopenia associated with chronic disease in adults with impaired protein utilization and reduced oral intake, under the supervision of a physician.

Adults in this group often struggle to meet their protein needs from meals, for example through reduced appetite, early satiety or difficulty finishing meals. Suitability for each patient is the clinician’s judgment.

Core ingredients

  • Whey protein. A complete protein, supplying all nine essential amino acids, including naturally occurring leucine. Whey protein is made from milk.
  • HMB (beta-hydroxy-beta-methylbutyrate). A compound the body makes in small amounts from leucine.
  • Vitamin D. Supports normal muscle function.

What the research supports, and what it does not

Expert groups recommend at least 1.0 to 1.2 g/kg/day of protein for adults over 65, and 1.2 to 1.5 g/kg/day with acute or chronic disease, except severe kidney disease not on dialysis.1,2 Many community-dwelling older adults eat less than this.3 In the PROVIDE trial, a related whey-protein formula with added leucine and vitamin D improved appendicular muscle mass and chair-stand time; handgrip strength and SPPB, the primary outcomes, did not differ between groups.4

Not established for CORUS

No study has tested CORUS. Its effect on muscle mass, strength, function or any other outcome is not established, and none is claimed. How much it adds to total daily protein, and its acceptability, tolerance and preparation in real foods, will be documented with the finished product. The trial formulas above added extra leucine; CORUS gets its leucine from whey protein.

For the full evidence, see the CORUS clinician development brief and the research reading list.

Prelaunch status, November 2026

  • Formula finalized. Label and product information sheet in preparation.
  • Regulatory. Being developed as a medical food under 21 U.S.C. 360ee(b)(3) and 21 CFR 101.9(j)(8). Label and claims wording are still in preparation. FDA does not approve medical foods before sale.
  • Availability. Not for sale. No samples, pricing, ordering or coverage information yet.

To be confirmed on the final label

Serving size and the amount of each ingredient; nutrition information; the full ingredient list and allergen statement; directions for use, including servings per day, suitable foods and preparation; storage and shelf life; and contraindications, tolerance and interactions.

Sources